Journal of Allergy and Clinical Immunology-In Practice

The Journal of Allergy and Clinical Immunology: In Practice is a peer-reviewed journal published by Elsevier on behalf of the American Academy of Allergy, Asthma and Immunology since 2013 that focuses on practical clinical information for allergists and immunologists, with a 2025 Journal Impact Factor of 7.2 and a first-quartile position in allergy《过敏与临床免疫学杂志（实践版）》是（Elsevier）代表美国过敏、哮喘与免疫学会（AAAAI）自 2013 年起出版的同行评议期刊，聚焦面向过敏科与免疫科医师的实用临床信息，2025 年影响因子 7.2，在过敏类别列第一四分位。

Scope

• It covers the spectrum of conditions treated by allergist-immunologists, including food allergy and eosinophilic gastrointestinal disorders该刊覆盖过敏科与免疫科医师诊治的各类病症，包括食物过敏与嗜酸细胞性胃肠道疾病。
• Respiratory disorders in scope include asthma, allergic and nonallergic rhinitis, nasal polyps, chronic sinusitis, chronic obstructive pulmonary disease and hypersensitivity pneumonitis范围内的呼吸系统疾病包括哮喘、过敏性与非过敏性鼻炎、鼻息肉、慢性鼻窦炎、慢性阻塞性肺疾病与过敏性肺炎。
• Drug allergy, insect sting allergy and anaphylaxis are core topics药物过敏、昆虫叮咬过敏与过敏性休克是核心主题。
• Dermatologic disorders covered include atopic dermatitis, contact dermatitis, urticaria, angioedema and hereditary angioedema涉及的皮肤病包括特应性皮炎、接触性皮炎、荨麻疹、血管性水肿与遗传性血管性水肿。
• Immunodeficiency and mast cell disorders are included, as are presenting symptoms such as cough, pruritus, rash, dyspnoea and eosinophilia涵盖免疫缺陷与肥大细胞疾病，以及咳嗽、瘙痒、皮疹、呼吸困难与嗜酸性粒细胞增多等就诊症状。
• The emphasis is on practical information clinicians can use in everyday practice, while mechanistic or translational studies without near-term clinical relevance and animal studies fall outside scope重点在于临床医师日常可用的实用信息，缺乏近期临床相关性的机制或转化研究以及动物研究不在范围内。
• For each original article a highlight box summarises what is already known, what the study adds and how it affects current management guidelines每篇原创文章均配要点框，概述已知内容、本研究新增发现及其对现行诊疗指南的影响。

History

• JACI: In Practice was launched by Elsevier in 2013 as an official publication of the American Academy of Allergy, Asthma and Immunology and a companion to the Journal of Allergy and Clinical Immunology该刊由（Elsevier）于 2013 年创办，是美国过敏、哮喘与免疫学会的官方出版物，也是（Journal of Allergy and Clinical Immunology）的姊妹刊。^[1]
• It was created to bring clinical papers, instructive case reports and management recommendations to practising allergists and other clinicians其创办宗旨是把临床论文、具启发性的病例报告与管理建议带给执业过敏科医师及其他临床医师。
• Its Journal Impact Factor moved from 8.861 in 2021 through 11.022 in 2022 and 6.6 in 2024 to 7.2 in 2025其影响因子由 2021 年的 8.861 经 2022 年的 11.022 与 2024 年的 6.6 升至 2025 年的 7.2。
• The journal is published 12 times a year and is largely subscription based, with open access options for individual articles该刊每年出版 12 期，以订阅制为主，并为单篇文章提供开放获取选项。
• It is indexed in the Science Citation Index Expanded and MEDLINE, and reports an average time to first decision of about 18 days该刊被（Science Citation Index Expanded）与（MEDLINE）收录，从投稿到首次决定的平均时间约为 18 天。
• Accepted articles appear online in less than seven days文章在接收后不到七天即在线上线。

Editors

• Michael Schatz, MD, MS, of San Diego, California, United States, is the Editor-in-Chief（Michael Schatz）医学博士、理学硕士为现任主编，常驻美国加利福尼亚州圣迭戈。
• Robert S. Zeiger and Scott H. Sicherer serve as Deputy Editors, and David A. Khan of Dallas, Texas, is an Associate Editor（Robert S. Zeiger）与（Scott H. Sicherer）任副主编，得克萨斯州达拉斯的（David A. Khan）为助理编辑。
• Dawn Angel of Denver, Colorado, is the Managing Editor科罗拉多州丹佛的（Dawn Angel）为执行编辑。
• The editorial board numbers dozens of members based in the United States as well as the Netherlands, the United Kingdom, Canada, France, Germany, Switzerland, Brazil and Australia编委会成员数十人，分布于美国以及荷兰、英国、加拿大、法国、德国、瑞士、巴西与澳大利亚。
• Board members include Hugh A. Sampson and Scott H. Sicherer of New York and Thomas A. E. Platts-Mills of Charlottesville in the United States编委包括纽约的（Hugh A. Sampson）与（Scott H. Sicherer），以及美国夏洛茨维尔的（Thomas A. E. Platts-Mills）。
• All content is peer-reviewed, and review articles that offer continuing medical education are primarily invited by the editors所有内容均经同行评议，提供继续医学教育的综述文章主要由编辑约稿。